A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs BIVV-009 (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Cadenza
- Sponsors Bioverativ
- 06 Mar 2018 According to a Bioverativ media release, first patient has been dosed in this trial.
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 22 Nov 2017 New trial record